Bayer: cancer drug Xofigo approved in China
(CercleFinance.com) - On Thursday Germany's Bayer announced that the Chinese drug agency has approved its alpha-immunotherapy Xofigo in the treatment of castration-resistant prostate cancer (mCRPC) accompanied by bone metastases.
Xofigo, an injectable solution of radium chloride that has already been approved in around 50 countries, including the United States, Europe and Japan, causes DNA breaks in cells adjacent to the tumour, which has an anti-tumor effect on bone metastases.
According to Bayer, 90% of patients with metastatic prostate cancer have bone metastases.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Xofigo, an injectable solution of radium chloride that has already been approved in around 50 countries, including the United States, Europe and Japan, causes DNA breaks in cells adjacent to the tumour, which has an anti-tumor effect on bone metastases.
According to Bayer, 90% of patients with metastatic prostate cancer have bone metastases.
Copyright (c) 2020 CercleFinance.com. All rights reserved.